FDA gives another year for biologics CMC pilot applications
This article was originally published in The Gold Sheet
FDA Sept. 17 pushed back the Sept. 30 deadline by a year for requests to participate in its chemistry, manufacturing and controls submission pilot for large-molecule products. FDA also expanded the slots for original applications to eight from five for the expanded change protocol pilot, patterned after a 2005 CMC pilot for applying new design space and risk-based concepts to small-molecule drugs
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.